GO Therapeutics Scientific Co-Founder & Chief Scientific Officer Hans Wandall, M.D., Ph.D. co-authors article published in British Journal of Cancer.
Dr. Zhukovsky is an accomplished leader in the development of immune-therapeutics, such as T-cell bispecifics and immune checkpoint inhibitors.
Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business development and alliance management for major pharmaceutical firms.
Strategic investment to help accelerate antibody development programs against novel solid tumor targets.